BackGT Biopharma Overview

GT Biopharma Receivables

Latest receivables for GTBP: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average

Loading

GT Biopharma Receivables History

Loading

GT Biopharma vs. peers: Receivables Comparison

Loading

GT Biopharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

GT Biopharma (GTBP) FAQ

The latest receivables for GTBP is $0 as of March 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside GT Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, GTBP's receivables moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GT Biopharma's operating scale or balance-sheet position.

A receivables figure of $0 for GTBP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GTBP's receivables ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack GT Biopharma's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.